|
INTRODUCTION
The Vaccine sector is entering a new era, with the recent and forthcoming launch of new, innovative high value products. These will shift the
market from being led by inclusion or otherwise onto high volume immunization schedules towards a new set of consumer orientated products.
SCOPE OF THE REPORT
- This In-Depth Analysis examines the prophylactic vaccine market, which targets three main patient groups, namely pediatric, the elderly and
travelers.
- An analysis of pipeline activity by indication, company, product type and delivery route.
- Licensing activity within the vaccine sector and key company profiles are also provided.
- Finally, strategic options to increase manufacturing capacity are discussed and analyzed.
REPORT HIGHLIGHTS
The launch and continued success of the high-value product, Prevnar, as demonstrated by 2002 year sales of $242m (11% market share - IMS Health),
indicates that future vaccine success will rely less heavily on high volume sales of multiple products. The introduction of individual high-value
products has the potential to revolutionize the competitive dynamics of the vaccine market away from its traditional high volume immunization schedule
reliance.
In order to sustain the recent rate of market growth (market growth 2000-2001 26.2%), companies are expanding vaccine portfolios into novel
indications and patient groups. Datamonitor believes that entry into niche disease areas should be treated with caution, as witnessed by the
withdrawal of GlaxoSmithKline's (GSK) LymeRix in early 2002, as a result of poor sales.
Although the current vaccine pipeline is dominated by smaller biotechnology companies (85% of those with developmental vaccines), Datamonitor
predicts that, in the long-term, there will be a decline in biotech involvement in this sector. This will stem from increased competition and an
associated reduction in licensing deals with major global pharmaceutical companies.
KEY REASONS TO BUY THIS REPORT
- Optimize R&D investment through an in-depth understanding of disease epidemiology and the current vaccine pipeline
- Assess key player vaccine activity in terms of product portfolios and partnership networks
- Gain insight into drivers behind current alliance activity and other key industry trends
- Identify alternative manufacturing strategies in order to boost capacity to meet increasing demand
| 
View Cart
